President Bush nominated acting FDA commissioner Andrew vonEschenbach, M.D., to permanently head the agency. Eschenbach, whoalso heads the National Cancer Institute, may faceconflict-of-interest charges at his confirmation hearings, andSenate Democrats have threatened to hold up his confirmation overFDA's inaction on OTC status for the emergency contraceptive PlanB. NCPA and NACDS had no comment on the Eschenbach nomination, butAPhA views him as an "excellent choice."
How Differences in Bispecific Therapies Impact Myeloma Treatment Operations
April 18th 2024According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.